Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology

The patent extends Pulmatrix's broad protection for its innovative technology to Europe
 
LEXINGTON, Mass., March 21, 2017 -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key patent from the European Union.
 
"This new patent shows our continued ability to obtain patents that protect our unique iSPERSE inhaled drug technology—and that also reflect the advances we are making in drug delivery," said Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. "It gives us a strong intellectual property protection position in Europe as we move forward with our drug candidates for COPD, fungal infections, and other diseases."
Read more: Pulmatrix Inc ( PULM )

IBEX earns $422,686 in fiscal Q2

Mr. Paul Baehr reports
 
IBEX REPORTS RESULTS FOR THE SECOND QUARTER AND THE SIX MONTHS ENDED JANUARY 31, 2017
 
IBEX Technologies Inc. has released its financial results for the six months ended Jan. 31, 2017.
 
"The second quarter of fiscal 2017 was a very positive quarter for the company with sales increasing 35 per cent over year ago and 27 per cent over the previous quarter," said Paul Baehr, IBEX president and chief executive officer. "Net earnings increased 114 per cent over the same quarter year ago and by 113 per cent over the previous quarter. In addition, cash and cash equivalents have increased by 8 per cent during the quarter despite the investment in our new fermentation facility.
Read more: Ibex Technologies Inc ( IBT )

NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain

NKTR-181 Significantly Reduced Pain in Patients with Moderate to Severe Chronic Low Back Pain
Primary Efficacy Endpoint Achieved (p=0.0019)
Analyst Conference Call and Webcast Today at 5:45 a.m. PDT/8:45 a.m. EDT
 
SAN FRANCISCO, March 20, 2017 / -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic.  NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.1  The U.S. Food and Drug Administration (FDA) has granted the investigational medicine NKTR-181 Fast Track designation for the treatment of moderate to severe chronic pain.
Read more: Nektar Therapeutics ( NKTR )

Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid

- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - 
- Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those with ASCVD and/or HeFH - 
- On Track to Submit NDA for an LDL-C Lowering Indication by 1H 2019 - 
- Conference Call and Webcast on Monday, March 20, 2017 at 8:00 a.m. Eastern Time -
 
ANN ARBOR, Mich., March 20, 2017 -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced the U.S. Food and Drug Administration (FDA) recently confirmed that Esperion’s LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid.
Read more: Esperion Therapeutics ( ESPR )

Threshold Pharmaceuticals and Molecular Templates Agree to Combine

-- Transaction to result in Nasdaq-listed company focused on developing novel treatments for cancer --
-- Molecular Templates lead drug candidate being developed to treat non-Hodgkin’s Lymphoma (NHL); engineered toxin body (ETB) platform has applications in multiple oncology indications --
-- Combined company will be capitalized to support advancement of MT-3724 through pivotal trial in NHL and evofosfamide through Phase 1b trial at MD Anderson Cancer Center --
-- $20 million investment by leading U.S. venture capital firm at the close of the transaction --
-- Conference call on March 17, 2017 at 8:30 a.m. ET --
 
SOUTH SAN FRANCISCO, Calif. and AUSTIN, Texas, March 17, 2017 -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, and Molecular Templates, Inc., a privately held biopharmaceutical company, today jointly announced that they have entered into a definitive agreement under which Molecular Templates will merge with a wholly owned subsidiary of Threshold in an all-stock transaction. The transaction will result in a combined company focused on the development of novel treatments for cancer.
Read more: Threshold Pharmaceuticals ( THLD )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker